JP6819012B2 - 癌と転移を処置するための低密度焦点式超音波 - Google Patents
癌と転移を処置するための低密度焦点式超音波 Download PDFInfo
- Publication number
- JP6819012B2 JP6819012B2 JP2017563052A JP2017563052A JP6819012B2 JP 6819012 B2 JP6819012 B2 JP 6819012B2 JP 2017563052 A JP2017563052 A JP 2017563052A JP 2017563052 A JP2017563052 A JP 2017563052A JP 6819012 B2 JP6819012 B2 JP 6819012B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- ultrasonic
- lofu
- cells
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 408
- 238000002604 ultrasonography Methods 0.000 title claims description 109
- 206010027476 Metastases Diseases 0.000 title description 27
- 201000011510 cancer Diseases 0.000 title description 20
- 238000011282 treatment Methods 0.000 claims description 261
- 239000002246 antineoplastic agent Substances 0.000 claims description 75
- 229940127089 cytotoxic agent Drugs 0.000 claims description 69
- 230000000638 stimulation Effects 0.000 claims description 50
- 238000002560 therapeutic procedure Methods 0.000 claims description 48
- 101100478278 Mus musculus Spta1 gene Proteins 0.000 claims description 37
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 10
- 101100478277 Homo sapiens SPTA1 gene Proteins 0.000 claims 1
- 102100037608 Spectrin alpha chain, erythrocytic 1 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 168
- 210000001744 T-lymphocyte Anatomy 0.000 description 125
- 241000699670 Mus sp. Species 0.000 description 102
- 210000004027 cell Anatomy 0.000 description 91
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 86
- 229950007866 tanespimycin Drugs 0.000 description 85
- 210000001519 tissue Anatomy 0.000 description 78
- 230000014509 gene expression Effects 0.000 description 60
- 201000001441 melanoma Diseases 0.000 description 48
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 45
- 238000001959 radiotherapy Methods 0.000 description 43
- 239000000427 antigen Substances 0.000 description 41
- 108091007433 antigens Proteins 0.000 description 41
- 102000036639 antigens Human genes 0.000 description 41
- 238000002512 chemotherapy Methods 0.000 description 41
- 238000002786 image-guided radiation therapy Methods 0.000 description 39
- 210000004881 tumor cell Anatomy 0.000 description 38
- 230000001965 increasing effect Effects 0.000 description 36
- 230000035882 stress Effects 0.000 description 36
- 210000004443 dendritic cell Anatomy 0.000 description 35
- 230000004906 unfolded protein response Effects 0.000 description 26
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 238000011394 anticancer treatment Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 238000002648 combination therapy Methods 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 102000000588 Interleukin-2 Human genes 0.000 description 20
- 108010002350 Interleukin-2 Proteins 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 230000004614 tumor growth Effects 0.000 description 19
- 238000009169 immunotherapy Methods 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 206010060862 Prostate cancer Diseases 0.000 description 17
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 17
- 230000004913 activation Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 230000009401 metastasis Effects 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 208000001382 Experimental Melanoma Diseases 0.000 description 15
- 238000003384 imaging method Methods 0.000 description 15
- 239000006166 lysate Substances 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000003753 real-time PCR Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 210000000130 stem cell Anatomy 0.000 description 13
- 230000001093 anti-cancer Effects 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 description 11
- 108091008010 PERKs Proteins 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 description 10
- 238000002271 resection Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 9
- 206010053759 Growth retardation Diseases 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 230000004915 chaperone-mediated autophagy Effects 0.000 description 9
- 231100000001 growth retardation Toxicity 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 230000000174 oncolytic effect Effects 0.000 description 9
- 230000003938 response to stress Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102000004082 Calreticulin Human genes 0.000 description 8
- 108090000549 Calreticulin Proteins 0.000 description 8
- 101150059401 EGR2 gene Proteins 0.000 description 8
- 206010027458 Metastases to lung Diseases 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 230000016914 response to endoplasmic reticulum stress Effects 0.000 description 8
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 7
- 102100022297 Integrin alpha-X Human genes 0.000 description 7
- 108010006519 Molecular Chaperones Proteins 0.000 description 7
- 230000005867 T cell response Effects 0.000 description 7
- 238000002591 computed tomography Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000001235 sensitizing effect Effects 0.000 description 7
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 6
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 6
- 102000005431 Molecular Chaperones Human genes 0.000 description 6
- 229940079156 Proteasome inhibitor Drugs 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 238000013439 planning Methods 0.000 description 6
- 208000023958 prostate neoplasm Diseases 0.000 description 6
- 239000003207 proteasome inhibitor Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 102100031853 Endoplasmic reticulum resident protein 44 Human genes 0.000 description 5
- 101710113885 Endoplasmic reticulum resident protein 44 Proteins 0.000 description 5
- -1 Nerarabin Chemical compound 0.000 description 5
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 229940034982 antineoplastic agent Drugs 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000000973 chemotherapeutic effect Effects 0.000 description 5
- 230000016396 cytokine production Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000004073 interleukin-2 production Effects 0.000 description 5
- 230000002601 intratumoral effect Effects 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 210000004705 lumbosacral region Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000012846 protein folding Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 4
- 101150116845 Cblb gene Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101710113864 Heat shock protein 90 Proteins 0.000 description 4
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 101710106224 Protein disulfide-isomerase A3 Proteins 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 4
- 230000017274 T cell anergy Effects 0.000 description 4
- 102100033763 Transducin-like enhancer protein 4 Human genes 0.000 description 4
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 4
- 230000000340 anti-metabolite Effects 0.000 description 4
- 229940100197 antimetabolite Drugs 0.000 description 4
- 239000002256 antimetabolite Substances 0.000 description 4
- 239000003972 antineoplastic antibiotic Substances 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical group ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 210000003739 neck Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- 230000009258 tissue cross reactivity Effects 0.000 description 4
- 101150118951 tle4 gene Proteins 0.000 description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108020005087 unfolded proteins Proteins 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000007372 Ataxin-1 Human genes 0.000 description 3
- 108010032963 Ataxin-1 Proteins 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 3
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101150112743 HSPA5 gene Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 3
- 101710151472 Neuroendocrine convertase 1 Proteins 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 102100040120 Prominin-1 Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000005006 adaptive immune system Anatomy 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 238000002266 amputation Methods 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- 230000004900 autophagic degradation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960001467 bortezomib Drugs 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 230000001112 coagulating effect Effects 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000001120 cytoprotective effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000004041 dendritic cell maturation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000037449 immunogenic cell death Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000003447 ipsilateral effect Effects 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000004142 macroautophagy Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000000861 pro-apoptotic effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical group C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 3
- 229960000977 trabectedin Drugs 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 230000005851 tumor immunogenicity Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- FABLAHMQSQFDHR-UHFFFAOYSA-N 3,3-bis(4-hydroxyphenyl)-7-methyl-1h-indol-2-one Chemical compound CC1=CC=CC2=C1NC(=O)C2(C=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 FABLAHMQSQFDHR-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100021807 ER degradation-enhancing alpha-mannosidase-like protein 1 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000895701 Homo sapiens ER degradation-enhancing alpha-mannosidase-like protein 1 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108091006081 Inositol-requiring enzyme-1 Proteins 0.000 description 2
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 101150039088 PDIA3 gene Proteins 0.000 description 2
- 102100037089 Protein disulfide-isomerase A4 Human genes 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 238000011398 antitumor immunotherapy Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 108010063267 endoplasmic reticulum glycoprotein p72 Proteins 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000009219 proapoptotic pathway Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000011517 stereotactic body radiotherapy Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- 238000002729 3-dimensional conformal radiation therapy Methods 0.000 description 1
- 238000011455 3D conformal radiation therapy Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010085376 Activating Transcription Factor 4 Proteins 0.000 description 1
- 102000007477 Activating Transcription Factor 4 Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000002664 Core Binding Factor Alpha 2 Subunit Human genes 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710156077 DNA damage-inducible transcript 3 protein Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 101710106383 Disulfide bond formation protein B Proteins 0.000 description 1
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 101150057663 Foxa2 gene Proteins 0.000 description 1
- 101150007884 Gata6 gene Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 description 1
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000017182 Ikaros Transcription Factor Human genes 0.000 description 1
- 108010013958 Ikaros Transcription Factor Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 101150113474 MAPK10 gene Proteins 0.000 description 1
- 101150031398 MAPK9 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101150101215 Mapk8 gene Proteins 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101100286111 Mus musculus Hoxa10 gene Proteins 0.000 description 1
- 101100286114 Mus musculus Hoxa11 gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101150008755 PCNA gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710116318 Probable disulfide formation protein Proteins 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100027224 Tumor protein p53-inducible nuclear protein 1 Human genes 0.000 description 1
- 108050003317 Tumor protein p53-inducible nuclear protein 1 Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108010088665 Zinc Finger Protein Gli2 Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000002091 elastography Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002665 ion therapy Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 201000001814 scrotum neoplasm Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 101150115978 tbx5 gene Proteins 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/06—Devices, other than using radiation, for detecting or locating foreign bodies ; Determining position of diagnostic devices within or on the body of the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Clinical applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
- A61B2018/00023—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids closed, i.e. without wound contact by the fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/374—NMR or MRI
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/378—Surgical systems with images on a monitor during operation using ultrasound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N2005/002—Cooling systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1048—Monitoring, verifying, controlling systems and methods
- A61N5/1049—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam
- A61N2005/1061—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using an x-ray imaging system having a separate imaging source
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0043—Ultrasound therapy intra-cavitary
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0056—Beam shaping elements
- A61N2007/0065—Concave transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0073—Ultrasound therapy using multiple frequencies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0078—Ultrasound therapy with multiple treatment transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0086—Beam steering
- A61N2007/0091—Beam steering with moving parts, e.g. transducers, lenses, reflectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0086—Beam steering
- A61N2007/0095—Beam steering by modifying an excitation signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- High Energy & Nuclear Physics (AREA)
- Human Computer Interaction (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Surgical Instruments (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170378P | 2015-06-03 | 2015-06-03 | |
| US62/170,378 | 2015-06-03 | ||
| US201562204312P | 2015-08-12 | 2015-08-12 | |
| US62/204,312 | 2015-08-12 | ||
| PCT/US2016/035440 WO2016196741A2 (en) | 2015-06-03 | 2016-06-02 | Low intensity focused ultrasound for treating cancer and metastasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020206143A Division JP7105294B2 (ja) | 2015-06-03 | 2020-12-11 | 癌と転移を処置するための低密度焦点式超音波 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517495A JP2018517495A (ja) | 2018-07-05 |
| JP2018517495A5 JP2018517495A5 (enExample) | 2019-07-04 |
| JP6819012B2 true JP6819012B2 (ja) | 2021-01-27 |
Family
ID=57442265
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563052A Active JP6819012B2 (ja) | 2015-06-03 | 2016-06-02 | 癌と転移を処置するための低密度焦点式超音波 |
| JP2020206143A Active JP7105294B2 (ja) | 2015-06-03 | 2020-12-11 | 癌と転移を処置するための低密度焦点式超音波 |
| JP2022111273A Active JP7635177B2 (ja) | 2015-06-03 | 2022-07-11 | 癌と転移を処置するための低密度焦点式超音波 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020206143A Active JP7105294B2 (ja) | 2015-06-03 | 2020-12-11 | 癌と転移を処置するための低密度焦点式超音波 |
| JP2022111273A Active JP7635177B2 (ja) | 2015-06-03 | 2022-07-11 | 癌と転移を処置するための低密度焦点式超音波 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10974077B2 (enExample) |
| EP (1) | EP3302264B1 (enExample) |
| JP (3) | JP6819012B2 (enExample) |
| CN (2) | CN108601554B (enExample) |
| WO (1) | WO2016196741A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021058618A (ja) * | 2015-06-03 | 2021-04-15 | モンテフィオーレ メディカル センターＭｏｎｔｅｆｉｏｒｅ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 癌と転移を処置するための低密度焦点式超音波 |
| US11179581B2 (en) | 2015-03-09 | 2021-11-23 | The Research Foundation For The State University Of New York | Systems and methods for promoting cellular activities for tissue maintenance, repair, and regeneration |
| US12434076B2 (en) | 2017-11-09 | 2025-10-07 | Montefiore Medical Center | Low energy immune priming for treating cancer and metastasis |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018071908A1 (en) | 2016-10-16 | 2018-04-19 | Vibrato Medical, Inc. | Extracorporeal therapeutic ultrasound for promoting angiogenesis |
| JP7408563B2 (ja) * | 2017-12-22 | 2024-01-05 | フリーダム ウェイブス エッセ．エッレ．エッレ． | 薬物の癌細胞へのソノポレーションを誘導するためのシステム及びその方法 |
| US11260249B2 (en) * | 2018-07-19 | 2022-03-01 | Sonablate Corp. | System, apparatus and method for high intensity focused ultrasound and tissue healing activation |
| JP2020110282A (ja) * | 2019-01-10 | 2020-07-27 | 治 三宅 | 生体用の超音波照射治療装置 |
| JP7474773B2 (ja) | 2019-02-13 | 2024-04-25 | アルフェウス メディカル，インク． | 非侵襲的音響化学療法 |
| WO2020165383A1 (fr) * | 2019-02-15 | 2020-08-20 | Boysset Max | Pièce d'habillement et méthode de contrôle de cellules utilisant une telle pièce d'habillement |
| CN110507917A (zh) * | 2019-07-30 | 2019-11-29 | 哈尔滨医科大学 | 一种超高场磁共振引导的低强度聚焦超声爆破系统 |
| CN114761076A (zh) * | 2019-08-27 | 2022-07-15 | 蒙特非奥里医疗中心 | 放射疗法的消融后调节 |
| US20210169979A1 (en) * | 2019-12-05 | 2021-06-10 | The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges | System and method for sonosensitized cancer immunotherapy with nanoparticles |
| CN116348146A (zh) * | 2020-08-06 | 2023-06-27 | 蒙特非奥里医疗中心 | 作为放射疗法的辅助的树突细胞活化疗法 |
| CA3185803A1 (en) | 2020-08-07 | 2022-02-10 | Vijay Agarwal | Ultrasound arrays for enhanced sonodynamic therapy for treating cancer |
| TWI843989B (zh) | 2021-02-19 | 2024-06-01 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之支架 |
| US12364880B2 (en) * | 2021-03-15 | 2025-07-22 | Guided Therapy Systems, Llc | Method for mid-intensity, non-ablative acoustic treatment of injured tissue |
| WO2023060199A1 (en) * | 2021-10-06 | 2023-04-13 | The Trustees Of Columbia University In The City Of New York | Method and integrated system for selective removal of defective cells and edematous fluids from the lung |
| US20250041577A1 (en) * | 2021-12-10 | 2025-02-06 | Insightec, Ltd. | Short-pulse sonodynamic treatment apparatus |
| US20230293913A1 (en) * | 2022-03-17 | 2023-09-21 | Open Water Internet Inc. | Harmonic excitation therapy and anti-tumor agent |
| WO2024042447A1 (en) | 2022-08-22 | 2024-02-29 | Laserleap Technologies, S.A. | Devices and methods for priming solid tumors with pressure pulses to enhance anticancer therapies |
| WO2024246914A1 (en) * | 2023-06-01 | 2024-12-05 | B.G. Negev Technologies And Applications Ltd. | Therapeutic ultrasound methods |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068961A3 (fr) | 1981-06-26 | 1983-02-02 | Thomson-Csf | Dispositif d'échauffement localisé de tissus biologiques |
| US7510536B2 (en) | 1999-09-17 | 2009-03-31 | University Of Washington | Ultrasound guided high intensity focused ultrasound treatment of nerves |
| AU1579901A (en) | 1999-11-01 | 2001-05-14 | University Of Cincinnati, The | Transcranial ultrasound thrombolysis system and method of treating a stroke |
| US6725095B2 (en) | 2000-04-13 | 2004-04-20 | Celsion Corporation | Thermotherapy method for treatment and prevention of cancer in male and female patients and cosmetic ablation of tissue |
| US6821274B2 (en) * | 2001-03-07 | 2004-11-23 | Gendel Ltd. | Ultrasound therapy for selective cell ablation |
| US20100087728A1 (en) | 2000-11-28 | 2010-04-08 | Physiosonics, Inc. | Acoustic palpation using non-invasive ultrasound techniques to identify and localize tissue eliciting biological responses |
| US20040034304A1 (en) | 2001-12-21 | 2004-02-19 | Chikayoshi Sumi | Displacement measurement method and apparatus, strain measurement method and apparatus elasticity and visco-elasticity constants measurement apparatus, and the elasticity and visco-elasticity constants measurement apparatus-based treatment apparatus |
| ES2315493T3 (es) * | 2002-05-23 | 2009-04-01 | Gendel Limited | Dispositivo de ablacion. |
| US7396336B2 (en) | 2003-10-30 | 2008-07-08 | Sherwood Services Ag | Switched resonant ultrasonic power amplifier system |
| US7896821B1 (en) * | 2003-11-14 | 2011-03-01 | Perfusion Technology, LLC | Low intensity directed ultrasound (LODUS) mediated blood brain barrier disruption |
| WO2005065371A2 (en) | 2003-12-30 | 2005-07-21 | Liposonix, Inc. | Systems and methods for the destruction of adipose tissue |
| AU2005213235A1 (en) | 2004-02-12 | 2005-08-25 | Neurosonix Ltd | Acoustic control of emboli in vivo |
| KR100537343B1 (ko) * | 2004-10-01 | 2005-12-19 | 주식회사 듀플로젠 | 관절염 치료용 초음파 장치 |
| WO2006050058A2 (en) | 2004-10-28 | 2006-05-11 | The General Hospital Corporation | Methods of detection and therapy of inflamed tissues using immune modulation |
| CN1814323B (zh) * | 2005-01-31 | 2010-05-12 | 重庆海扶(Hifu)技术有限公司 | 一种聚焦超声波治疗系统 |
| US7194063B2 (en) | 2005-02-10 | 2007-03-20 | Brookhaven Science Associates, Llc | Methods for implementing microbeam radiation therapy |
| WO2006113794A2 (en) | 2005-04-20 | 2006-10-26 | Richard Blankenbecler | Treatment to reduce damage from radiation therapy |
| EP1904179A2 (en) * | 2005-06-07 | 2008-04-02 | Koninklijke Philips Electronics N.V. | Method and apparatus for ultrasound drug delivery and thermal therapy with phase-convertible fluids |
| JP4369907B2 (ja) * | 2005-07-01 | 2009-11-25 | 株式会社日立製作所 | 音響化学治療装置 |
| KR20080039925A (ko) | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | 생물학적 모델에 기초하여 방사선 요법 치료 계획을적합화시키는 방법 및 시스템 |
| WO2007044469A2 (en) * | 2005-10-05 | 2007-04-19 | Perfusion Technology, Llp | A method and apparatus to direct radiation treatment to a specific region of the brain |
| US20070088345A1 (en) | 2005-10-13 | 2007-04-19 | Ust Inc. | Applications of HIFU and chemotherapy |
| WO2010029556A1 (en) * | 2008-09-12 | 2010-03-18 | Slender Medical, Ltd. | A device for ultrasound treatment and monitoring tissue treatment |
| JP5032094B2 (ja) * | 2006-11-06 | 2012-09-26 | テルモ株式会社 | 超音波診断装置および制御プログラム |
| US20080317204A1 (en) | 2007-03-16 | 2008-12-25 | Cyberheart, Inc. | Radiation treatment planning and delivery for moving targets in the heart |
| CN101820949B (zh) | 2007-03-30 | 2017-05-24 | 皇家飞利浦电子股份有限公司 | 用于引导放疗和其他过程的mri引导的hifu标记法 |
| US20100092424A1 (en) | 2007-11-21 | 2010-04-15 | Sanghvi Narendra T | Method of diagnosis and treatment of tumors using high intensity focused ultrasound |
| WO2009070677A1 (en) | 2007-11-28 | 2009-06-04 | Reliant Technologies, Inc. | Nonablative and ablative tissue treatment method and device |
| US8466605B2 (en) * | 2008-03-13 | 2013-06-18 | Ultrashape Ltd. | Patterned ultrasonic transducers |
| US20100286673A1 (en) | 2008-03-17 | 2010-11-11 | Palomar Medical Technologies, Inc. | Method and apparatus for treatment of tissue |
| WO2010009141A1 (en) | 2008-07-14 | 2010-01-21 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Methods and devices for modulating cellular activity using ultrasound |
| US8962290B2 (en) | 2008-08-26 | 2015-02-24 | Intelligentnano Inc. | Enhanced animal cell growth using ultrasound |
| CN101642607B (zh) * | 2009-09-01 | 2012-11-28 | 西安交通大学 | 基于阵列换能器的低强度聚焦超声药物控释与监控装置 |
| CN101690677B (zh) * | 2009-10-13 | 2011-09-21 | 西安交通大学 | 聚焦超声治疗组合阵元相控阵及多焦点剪切波成像系统 |
| US20130144192A1 (en) * | 2011-07-17 | 2013-06-06 | Neurotrek, Inc. | Ultrasound neuromodulation treatment of anxiety (including panic attacks) and obsessive-compulsive disorder |
| GB2479598B (en) * | 2010-04-16 | 2012-11-21 | Cancercure Technology As | Methods and systems for inducing hyperthermia |
| BR112012029726A2 (pt) * | 2010-05-27 | 2017-09-26 | Koninl Philips Electronics Nv | método para a operação de um transdutor ultrassônico, transdutor ultrassônico para a geração seletiva de ondas ultrassônicas e calor, e sistema para análise de amostra |
| US8777854B2 (en) * | 2011-09-06 | 2014-07-15 | General Electric Company | Method and system for ultrasound based automated detection, quantification and tracking of pathologies |
| US20140058293A1 (en) * | 2012-05-23 | 2014-02-27 | Sunnybrook Research Institute | Multi-Frequency Ultrasound Device and Method of Operation |
| EP2864792A1 (en) | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| CA2878491A1 (en) * | 2012-07-08 | 2014-01-16 | Sunnybrook Health Sciences Centre | System and method for using ultrasound-stimulated microbubble exposures to induce ceramide accumulation in endothelial and tumor cells |
| CN104582587A (zh) * | 2012-07-30 | 2015-04-29 | 诺森有限公司 | 具有倾斜度信息的超声波探测器和使用该探测器进行超声波诊断和治疗的设备 |
| CN102831716A (zh) * | 2012-08-27 | 2012-12-19 | 曲宝源 | 预付费球形膨胀腔低压损立柱式超声波热量表 |
| US9061133B2 (en) * | 2012-12-27 | 2015-06-23 | Brainsonix Corporation | Focused ultrasonic transducer navigation system |
| AU2014207272A1 (en) * | 2013-01-18 | 2015-07-30 | Neal D. Andruska | Estrogen receptor inhibitors |
| CN203112640U (zh) * | 2013-02-05 | 2013-08-07 | 韩先锋 | 旋流分区式船舶压载水处理装置 |
| US10960233B2 (en) | 2013-03-06 | 2021-03-30 | B.G. Negev Technologies And Applications Ltd. | Low intensity ultrasound therapy |
| WO2014145007A1 (en) | 2013-03-15 | 2014-09-18 | Eagleyemed | Ultrasound probe |
| CN103230648B (zh) * | 2013-04-24 | 2016-09-14 | 重庆医科大学 | 低强度聚焦超声分子显像与治疗系统 |
| WO2015067786A1 (en) * | 2013-11-08 | 2015-05-14 | Koninklijke Philips N.V. | Medical apparatus for radiotherapy and ultrasound heating |
| CN110575244A (zh) | 2013-11-19 | 2019-12-17 | 伊西康公司 | 用于治疗支气管疾病的胸腔镜方法 |
| TW201521671A (zh) * | 2013-12-11 | 2015-06-16 | Univ Nat Taiwan | 超音波醫療裝置 |
| US11547300B2 (en) | 2014-01-31 | 2023-01-10 | The General Hospital Corporation | Methods of treating and imaging tumor micrometastases using photoactive immunoconjugates |
| KR102465947B1 (ko) | 2014-04-18 | 2022-11-10 | 얼테라, 인크 | 밴드 트랜스듀서 초음파 치료 |
| EP3247280B1 (en) | 2015-01-15 | 2023-07-12 | Herring, Rodney | Diffuse acoustic confocal imager |
| CN104874114A (zh) | 2015-06-01 | 2015-09-02 | 天津大学 | 一种利用低强度超声促进放射治疗效应的系统 |
| US10974077B2 (en) | 2015-06-03 | 2021-04-13 | Montefiore Medical Center | Low intensity focused ultrasound for treating cancer and metastasis |
| WO2017079431A1 (en) | 2015-11-05 | 2017-05-11 | The General Hospital Corporation | Methods for treating cancer by enhancing intratumoral immune response |
| KR101875111B1 (ko) | 2016-04-29 | 2018-07-09 | 한국수력원자력 주식회사 | 저선량 방사선을 이용한 암화유전자 Ras-유도 악성 암화 억제 |
| US20180154183A1 (en) | 2016-06-22 | 2018-06-07 | Velayudhan Sahadevan | Normal Tissue Toxicity Reducing Microbeam-Broadbeam Radiotherapy, Skin's Radio-Response Immunotherapy and Mutated Molecular Apheresis Combined Cancer Treatments |
| US11684802B2 (en) | 2016-12-31 | 2023-06-27 | Radiation Barrier Llc | Reducing damage from radiation therapy and increasing cancer kill rates by interweaving of low and high dose sessions |
| MX2019007729A (es) | 2016-12-31 | 2019-08-29 | Radiation Barrier Llc | Reducción del daño de la quimioterapia y aumento de las tasas de destrucción de cáncer usando radiación entremezclada de baja dosis. |
| WO2019094802A1 (en) | 2017-11-09 | 2019-05-16 | Montefiore Medical Center | Low energy immune priming for treating cancer and metastasis |
| WO2020123388A1 (en) | 2018-12-11 | 2020-06-18 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| CN114761076A (zh) | 2019-08-27 | 2022-07-15 | 蒙特非奥里医疗中心 | 放射疗法的消融后调节 |
-
2016
- 2016-06-02 US US15/578,892 patent/US10974077B2/en active Active
- 2016-06-02 JP JP2017563052A patent/JP6819012B2/ja active Active
- 2016-06-02 CN CN201680045882.0A patent/CN108601554B/zh active Active
- 2016-06-02 CN CN202210152097.2A patent/CN114886412B/zh active Active
- 2016-06-02 WO PCT/US2016/035440 patent/WO2016196741A2/en not_active Ceased
- 2016-06-02 EP EP16804398.2A patent/EP3302264B1/en active Active
-
2020
- 2020-12-11 JP JP2020206143A patent/JP7105294B2/ja active Active
-
2021
- 2021-03-03 US US17/191,497 patent/US12011619B2/en active Active
-
2022
- 2022-07-11 JP JP2022111273A patent/JP7635177B2/ja active Active
-
2024
- 2024-05-08 US US18/658,055 patent/US20240366964A1/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11179581B2 (en) | 2015-03-09 | 2021-11-23 | The Research Foundation For The State University Of New York | Systems and methods for promoting cellular activities for tissue maintenance, repair, and regeneration |
| JP2021058618A (ja) * | 2015-06-03 | 2021-04-15 | モンテフィオーレ メディカル センターＭｏｎｔｅｆｉｏｒｅ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 癌と転移を処置するための低密度焦点式超音波 |
| JP7105294B2 (ja) | 2015-06-03 | 2022-07-22 | モンテフィオーレ メディカル センター | 癌と転移を処置するための低密度焦点式超音波 |
| JP2022165965A (ja) * | 2015-06-03 | 2022-11-01 | モンテフィオーレ メディカル センター | 癌と転移を処置するための低密度焦点式超音波 |
| JP7635177B2 (ja) | 2015-06-03 | 2025-02-25 | モンテフィオーレ メディカル センター | 癌と転移を処置するための低密度焦点式超音波 |
| US12434076B2 (en) | 2017-11-09 | 2025-10-07 | Montefiore Medical Center | Low energy immune priming for treating cancer and metastasis |
Also Published As
| Publication number | Publication date |
|---|---|
| US10974077B2 (en) | 2021-04-13 |
| EP3302264B1 (en) | 2025-03-19 |
| WO2016196741A3 (en) | 2017-05-04 |
| US20240366964A1 (en) | 2024-11-07 |
| JP2022165965A (ja) | 2022-11-01 |
| WO2016196741A2 (en) | 2016-12-08 |
| JP7635177B2 (ja) | 2025-02-25 |
| JP2018517495A (ja) | 2018-07-05 |
| US20210268315A1 (en) | 2021-09-02 |
| JP7105294B2 (ja) | 2022-07-22 |
| EP3302264A2 (en) | 2018-04-11 |
| CN114886412B (zh) | 2025-06-24 |
| EP3302264A4 (en) | 2019-02-20 |
| CN108601554B (zh) | 2022-03-08 |
| US12011619B2 (en) | 2024-06-18 |
| US20180296859A1 (en) | 2018-10-18 |
| CN108601554A (zh) | 2018-09-28 |
| CN114886412A (zh) | 2022-08-12 |
| JP2021058618A (ja) | 2021-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6819012B2 (ja) | 癌と転移を処置するための低密度焦点式超音波 | |
| US12434076B2 (en) | Low energy immune priming for treating cancer and metastasis | |
| Abdo et al. | Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers | |
| Bandyopadhyay et al. | Low-intensity focused ultrasound induces reversal of tumor-induced T cell tolerance and prevents immune escape | |
| Anzengruber et al. | T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it? | |
| Drake | Combination immunotherapy approaches | |
| De La Maza et al. | In situ vaccination after accelerated hypofractionated radiation and surgery in a mesothelioma mouse model | |
| Sidana | Cancer immunotherapy using tumor cryoablation | |
| Imran et al. | Magic bubbles: utilizing histotripsy to modulate the tumor microenvironment and improve systemic anti-tumor immune responses | |
| Preise et al. | Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP) | |
| Takahashi et al. | Immunological effect of local ablation combined with immunotherapy on solid malignancies | |
| Marabelle et al. | Radiotherapy and toll-like receptor agonists | |
| Imran et al. | Exploration of novel pathways underlying irreversible electroporation induced anti-tumor immunity in pancreatic cancer | |
| Sathianathen et al. | The current status of immunobased therapies for metastatic renal-cell carcinoma | |
| Cao et al. | Trehalose enhanced cold atmospheric plasma-mediated cancer treatment | |
| Byrne et al. | CD40 therapy and surgery: a potential immunologic partnership | |
| Nierkens et al. | Radiofrequency ablation in cancer therapy: Tuning in to in situ tumor vaccines | |
| US20170021002A1 (en) | Augmentation of cancer and cancer endothelial vaccine immunogenicity by histone deacetylase inhibitors | |
| HK1261209B (zh) | 用於治疗癌症和转移的低强度聚焦超声 | |
| HK1261209A1 (en) | Low intensity focused ultrasound for treating cancer and metastasis | |
| Alexander et al. | Immune effects of ablation | |
| Guha et al. | Immune System Modulation with LOFU And HIFU Treatment of Prostate Cancer | |
| Zhu et al. | The combination of local treatment and immunotherapy | |
| Skalina | Generation of an In Situ Tumor Vaccine Using Focused Ultrasound-Induced Immune Priming | |
| Singh | Role of Focused Ultrasound in CD40 Mediated Anti-Tumor Immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190529 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190530 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200522 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200903 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201116 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201211 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6819012 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |